Cargando…

Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study

OBJECTIVE: Owing to lower mean uric acid excretion in women compared with men, uricosuric agents might be preferred in women over xanthine oxidase (XO) inhibitors. We therefore investigated the differences in response to two urate-lowering therapies (ULTs) with different modes of action within and b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veenstra, Frouwke, Wanten, Sophie A C, Verhoef, Lise M, ter Stal, Minke, Kwok, Wing-Yee, van den Hoogen, Frank H J, Flendrie, Marcel, van Herwaarden, Noortje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Concise Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878845/ https://www.ncbi.nlm.nih.gov/pubmed/33604505 http://dx.doi.org/10.1093/rap/rkab002

Ejemplares similares

Effect of metformin use on clinical outcomes and serum urate in gout patients with diabetes mellitus: a retrospective cohort study
por: Veenstra, Frouwke, et al.
Publicado: (2022)

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
por: Kang, Eun Ha, et al.
Publicado: (2021)

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
por: Eun, Yeonghee, et al.
Publicado: (2022)

Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2022)

Allopurinol, Benzbromarone, or a Combination in Treating Patients with Gout: Analysis of a Series of Outpatients
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2014)

Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study
por: Veenstra, Frouwke, et al.
Publicado: (2023)

Reduced Incidence of Stroke in Patients with Gout Using Benzbromarone
por: Niu, Sheng-Wen, et al.
Publicado: (2022)

Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial
por: Peeters, Iris Rose, et al.
Publicado: (2023)

Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit
por: Ulijn, Evy, et al.
Publicado: (2022)

A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia
por: Lai, Shih-Wei, et al.
Publicado: (2021)

Tele-monitoring flares using a smartphone app in patients with gout or suspected gout: a feasibility study
por: Pouls, Bart P H, et al.
Publicado: (2021)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study
por: Xue, Xiaomei, et al.
Publicado: (2022)

The risk of ischemic cerebrovascular disease associated with benzbromarone use in gout people: A retrospective cohort study in Taiwan
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Gout, flares, and allopurinol use: a population-based study
por: Proudman, Charlotte, et al.
Publicado: (2019)

Reasons for discontinuing urate-lowering treatment in community-dwelling adults with gout: results of a primary care-based cross-sectional study
por: Elmelegy, Dalia, et al.
Publicado: (2021)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes
por: Singh, Jasvinder A., et al.
Publicado: (2017)

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2022)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Predominant HLA Alleles and Haplotypes in Mild Adverse Drug Reactions Caused by Allopurinol in Vietnamese Patients with Gout
por: Van Son, Chu, et al.
Publicado: (2021)

Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation
por: López, Laura C., et al.
Publicado: (2016)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study
por: Xue, Xiaomei, et al.
Publicado: (2020)

Superiority of Low‐Dose Benzbromarone to Low‐Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion
por: Yan, Fei, et al.
Publicado: (2022)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Gao, Linggen, et al.
Publicado: (2021)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Retraction Note: Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
por: Ali, Zakir, et al.
Publicado: (2023)

The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by Benzbromarone
por: Tadjuidje, Emmanuel, et al.
Publicado: (2012)

Benzbromarone Stabilizes ΔF508 CFTR at the Cell Surface
por: Loo, Tip W., et al.
Publicado: (2011)

Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
por: Dalbeth, Nicola, et al.
Publicado: (2018)

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
por: Zhang, Shengzhao, et al.
Publicado: (2021)

Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis
por: Deng, Jian‐Hao, et al.
Publicado: (2022)

Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
por: Dewi, Christiyanti, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c67jsamn0r6g7vk1cvhk1vvn5r